氟卡尼Brugada考试综合症:可再生的,但风险的工具。
文章的细节
-
引用
复制到剪贴板 -
Gasparini M,先天SG, Mantica M,纳波利塔诺C, Galimberti P, Ceriotti C, Simonini年代
氟卡尼Brugada考试综合症:可再生的,但风险的工具。
踱步Electrophysiol。2003年1月,26 (1 Pt (2): 338 - 41。
- PubMed ID
-
12687841 (在PubMed]
- 文摘
-
氟卡尼测试广泛应用于Brugada综合症。然而,它的再现性和安全性仍然是不明确的。本研究包括22名患者(18人,平均年龄34岁)。SCN5A基因的突变被发现在8个病人。两个心脏性猝死患者流产,8晕厥/晕厥先兆,12人无症状。心电图是诊断19病人和暗示3。在基线,21岁的22名患者接受了氟卡尼测试(2毫克/公斤四丸超过10分钟)。21日21患者测试诊断或放大典型的心电图模式。输注结束时,持续开发的VT 7 - 10分钟两个病人。第二个氟卡尼在20例测试2个月内进行。 The test was not repeated in the two patients with prior development of VT. The flecainide test was diagnostic in 20 of 20 patients. Sustained VT occurred in one patient and recurrent VF in another. The reproducibility of the flecainide test was 100%. In 4 (18%) of 22 patients major VAs were documented after the end of flecainide infusion. VA occurred in 3 (43%) of 7 patients with, versus 1 (7%) 15 without SCN5A gene mutation (P < 0.05). No diagnostic ECG changes or arrhythmias developed in 25 control patients without structural heart disease who underwent the same study protocol. This study shows a high flecainide reproducibility, supporting its diagnostic value in Brugada syndrome. However, the occurrence of major VA, significantly higher in patients with documented SCN5A gene mutation, including in asymptomatic patients, mandates the performance under appropriate medical supervision. Whether a slower rate of drug infusion can lower the risk of VA induction, while maintaining the sensitivity of the test should be explored.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物